Abbvie Inc. vs Quest Diagnostics Inc.
ABBV vs DGX — side-by-side comparison from reported financials. ABBV leads 6, DGX leads 5 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Quest Diagnostics Inc.
DGX · Healthcare
$230.97+0.07%Mixed
| Metric | ABBV | DGX |
|---|---|---|
| Price | $276.43 | $230.97 |
| Market cap | $488B | $25.5B |
| Revenue (TTM) | $64.4B | $11.6B |
| Revenue growth | +1.8% | +3.7% |
| Net margin | 9.8% | 9.2% |
| Free cash flow | $18.2B | $1.35B |
| Net cash (debt) | ($56.2B) | ($4.75B) |
| 1-year price return | +19.8% | +27.3% |
| P/E | 77.4 | 24.0 |
| P/E vs own history (cheap-side %) | 23% | 5% |
| Dividend yield | 2.45% | 1.42% |
| Return on equity | 96% | 14% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 57,000 |
Full résumé-style profiles: ABBV CV · DGX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.